In Q4, Eli Lilly reported EPS at $5.32, up from $2.49 in the same quarter last year. This print beat analysts’ estimates by 4.7%. Over the next 12 months, Wall Street expects Eli Lilly’s full ...

Parnassus Investments, an investment management company, released the “Parnassus Core Equity Fund” fourth quarter 2024 ...

Eli Lilly's stock is undervalued; defensive healthcare stocks shine amid uncertainty, and Eli Lilly drives growth. Click here ...

Mike, please go ahead. Good morning, thank you for joining us for Eli Lilly and Company's Q4 2024 earnings call. I'm Mike Czapar, Senior Vice President of Investor Relations. Joining me on today's ...

Recent developments at Eli Lilly (NYSE:LLY) have highlighted significant strides in both product innovation and operational ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Eli Lilly has lowered the price of its weight-loss drug Zepbound for patients paying out of pocket and introduced two new available vial doses.

Eli Lilly and Company ( NYSE:LLY – Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing the ...

We recently compiled a list of the Top 10 Stocks to Buy According to Lone Pine Capital. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the ...

Eli Lilly & Co.’s stock rose 1.6% Wednesday, after the drug company announced plans to expand its U.S. manufacturing sites by adding four more locations this year, along with 13,000 high-wage jobs.

Hims & Hers Health (HIMS) is an intriguing stock strategically positioned in the rapidly expanding telehealth market. However, this week’s ...

Global pharmaceutical company Eli Lilly (NYSE:LLY) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 44.7% year on year to $13.53 billion. The company’s full-year revenue ...